Conditions: Carcinoma, Non Small Cell Lung
Keywords: Phalcis BRCA1 RAP80 TS First line Non-squamous
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 57
Healthy volunteers: no

Brief summary:
This is a study of pemetrexed disodium plus cisplatin as first-line therapy in patients with advanced non-squamous cell lung cancer. This is a phase IIA pharmacogenomic trial.

Detailed description:
This is a non-randomized, phase IIA pharmacogenomic, open label, uncontrolled, efficacy study in patients with advanced non-squamous cell lung cancer as a first line therapy.

Arms:
arm 1: pemetrexed 500 mg/m2 IV + cisplatin 75 mg/m2 every 21 days

Interventions: intervention 1: Pemetrexed/Cisplatin
Intervention descriptions: intervention 1: Pemetrexed 500 mg/m2 IV followed by cisplatin 75 mg/m2 IV every 21 days. A cycle is 21 day.

Protocol document: